Long NP - Search Results

1

Semi-Automated Therapeutic Drug Monitoring as a Pillar toward Personalized Medicine for Tuberculosis Management.

Jayanti RP, Long NP, Phat NK, Cho YS, Shin JG. Jayanti RP, et al. Among authors: long np. Pharmaceutics. 2022 May 5;14(5):990. doi: 10.3390/pharmaceutics14050990. Pharmaceutics. 2022. PMID: 35631576 Free PMC article. Review.

2

Metabolomics-guided global pathway analysis reveals better insights into the metabolic alterations of breast cancer.

Long NP, Heo D, Kim HY, Kim TH, Shin JG, Lee A, Kim DH. Long NP, et al. J Pharm Biomed Anal. 2021 Aug 5;202:114134. doi: 10.1016/j.jpba.2021.114134. Epub 2021 May 13. J Pharm Biomed Anal. 2021. PMID: 34052553

3

Isoniazid Population Pharmacokinetics and Dose Recommendation for Korean Patients With Tuberculosis Based on Target Attainment Analysis.

Cho YS, Jang TW, Kim HJ, Oh JY, Lee HK, Park HK, Ghim JL, Long NP, Park Y, Choi YK, Phuong NTT, Shin JG; Center for Personalized Precision Medicine of Tuberculosis. Cho YS, et al. Among authors: long np. J Clin Pharmacol. 2021 Dec;61(12):1567-1578. doi: 10.1002/jcph.1931. Epub 2021 Jul 26. J Clin Pharmacol. 2021. PMID: 34157153

4

A 10-gene biosignature of tuberculosis treatment monitoring and treatment outcome prediction.

Long NP, Phat NK, Yen NTH, Park S, Park Y, Cho YS, Shin JG. Long NP, et al. Tuberculosis (Edinb). 2021 Dec;131:102138. doi: 10.1016/j.tube.2021.102138. Epub 2021 Oct 8. Tuberculosis (Edinb). 2021. PMID: 34801869

5

Development of population pharmacokinetics model of isoniazid in Indonesian patients with tuberculosis.

Soedarsono S, Jayanti RP, Mertaniasih NM, Kusmiati T, Permatasari A, Indrawanto DW, Charisma AN, Yuliwulandari R, Long NP, Choi YK, Hoa PQ, Hoa PV, Cho YS, Shin JG. Soedarsono S, et al. Among authors: long np. Int J Infect Dis. 2022 Apr;117:8-14. doi: 10.1016/j.ijid.2022.01.003. Epub 2022 Jan 10. Int J Infect Dis. 2022. PMID: 35017103 Free article.

6

Delineation of the molecular mechanisms underlying Colistin-mediated toxicity using metabolomic and transcriptomic analyses.

Long NP, Oh JH, Park SM, Yen NTH, Phat NK, Cho YS, Kim HM, Yoon S, Shin JG, Kim DH. Long NP, et al. Toxicol Appl Pharmacol. 2022 Mar 15;439:115928. doi: 10.1016/j.taap.2022.115928. Epub 2022 Feb 19. Toxicol Appl Pharmacol. 2022. PMID: 35189178

7

Characterization of Clofazimine as a Potential Substrate of Drug Transporter.

Jony MR, Cho YS, Long NP, Shin HJ, Shin JG. Jony MR, et al. Among authors: long np. Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0215821. doi: 10.1128/aac.02158-21. Epub 2022 Mar 7. Antimicrob Agents Chemother. 2022. PMID: 35254089 Free PMC article.

8

Center for Personalized Precision Medicine for Tuberculosis: Smart Research and Development Workstation.

Nguyen VL, Ahn S, Hoa PQ, Long NP, Ahn S, Cho YS, Shin JG. Nguyen VL, et al. Among authors: long np. Healthc Inform Res. 2022 Apr;28(2):176-180. doi: 10.4258/hir.2022.28.2.176. Epub 2022 Apr 30. Healthc Inform Res. 2022. PMID: 35576986 Free PMC article. No abstract available.

9

Genome-wide gene expression analysis reveals molecular insights into the drug-induced toxicity of nephrotoxic agents.

Yen NTH, Park SM, Thu VTA, Phat NK, Cho YS, Yoon S, Shin JG, Kim DH, Oh JH, Long NP. Yen NTH, et al. Among authors: long np. Life Sci. 2022 Oct 1;306:120801. doi: 10.1016/j.lfs.2022.120801. Epub 2022 Jul 16. Life Sci. 2022. PMID: 35850247

10

Comprehensive lipid and lipid-related gene investigations of host immune responses to characterize metabolism-centric biomarkers for pulmonary tuberculosis.

Long NP, Anh NK, Yen NTH, Phat NK, Park S, Thu VTA, Cho YS, Shin JG, Oh JY, Kim DH. Long NP, et al. Sci Rep. 2022 Aug 4;12(1):13395. doi: 10.1038/s41598-022-17521-4. Sci Rep. 2022. PMID: 35927287 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

77 results

Search Page